Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Pharma-Bio Serv (PBSV) Free Cash Flow (2016 - 2026)

Pharma-Bio Serv's Free Cash Flow history spans 17 years, with the latest figure at -$392550.0 for Q1 2026.

  • For Q1 2026, Free Cash Flow rose 8.6% year-over-year to -$392550.0; the TTM value through Jan 2026 reached -$184594.0, up 90.19%, while the annual FY2025 figure was -$221530.0, 69.5% up from the prior year.
  • Free Cash Flow reached -$392550.0 in Q1 2026 per PBSV's latest filing, down from $279316.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $1.1 million in Q3 2022 to a low of -$700744.0 in Q2 2024.
  • Average Free Cash Flow over 5 years is $65669.0, with a median of -$78590.0 recorded in 2024.
  • Peak YoY movement for Free Cash Flow: tumbled 179.32% in 2024, then surged 455.41% in 2025.
  • A 5-year view of Free Cash Flow shows it stood at $247954.0 in 2022, then increased by 25.03% to $310016.0 in 2023, then plummeted by 125.35% to -$78590.0 in 2024, then soared by 455.41% to $279316.0 in 2025, then plummeted by 240.54% to -$392550.0 in 2026.
  • Per Business Quant, the three most recent readings for PBSV's Free Cash Flow are -$392550.0 (Q1 2026), $279316.0 (Q4 2025), and $234488.0 (Q3 2025).